WASHINGTON — One of the Food and Drug Administration’s top officials says that consolidation in the drug distributor market has made it less attractive for companies to sell generic drugs — and that raising prices of the drugs might actually invite more competition.
“This is a silent crisis,” said Janet Woodcock, director of the Center for Drug Evaluation and Research, said Friday. “It’s very bad.”
Another “Crisis” created by Industry Insiders and Pharma Lobbyists. We need to Privatize these operations to ensure a steady supply of inexpensive medications. Clearly the Industry has run it’s course. If it weren’t for these insiders and the corrupt politicians we would not be here now.
This is actually an old issue we have dealt with over many years and makes sense. Having sat on Pharmacy GPO Committees while in hospital practice, working at a GPO and in industry with some generic SKUs and drugs, we dealt with this. In industry, we actually tried to negotiate a highe price model, with guaranteed supply. Selling drugs as a lost leader at or below manufacturing cost is a poor clinical/financial model. Number one, we need drugs to treat patients and two, what is fair market value.